The FDA approved enfortumab vedotin-ejfv (Padcev, Astellas Pharma) to treat adults with locally advanced or metastatic urothelial cancer (UC) who have previously received a programmed death-1 (PD-1)/programmed death ligand-1 (PD-L1) inhibitor and platinum-containing chemotherapy or are ineligible for cisplatin-containing chemotherapy and have previously received one or more prior lines of therapy.
In December 2019, the FDA had granted accelerated approval to enfortumab vedotin (EV) in this